Home > Insider Trading > Filing (0001209191-21-012111)

Filing Details

Accession Number:: 0001209191-21-012111
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-02-18 18:59:48
Reporting Period:: 2020-02-18

Accepted Time:: 2021-02-18 18:59:48
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1000694	Novavax Inc	NVAX	Biological Products, (No Disgnostic Substances) (2836)	222816046

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1342823	M Gregory Glenn	C/O Novavax, Inc. 21 Firstfield Road Gaithersburg MD 20878	President, R&D	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2021-02-18	80	$264.09	5,165	No	4	S	Direct
Common Stock	Disposition	2021-02-18	361	$265.52	4,804	No	4	S	Direct
Common Stock	Disposition	2021-02-18	128	$266.68	4,676	No	4	S	Direct
Common Stock	Disposition	2021-02-18	268	$268.19	4,408	No	4	S	Direct
Common Stock	Disposition	2021-02-18	678	$269.23	3,730	No	4	S	Direct
Common Stock	Disposition	2021-02-18	319	$269.93	3,411	No	4	S	Direct
Common Stock	Disposition	2021-02-18	110	$271.16	3,301	No	4	S	Direct
Common Stock	Disposition	2021-02-18	205	$272.43	3,096	No	4	S	Direct
Common Stock	Disposition	2021-02-18	67	$273.61	3,029	No	4	S	Direct
Common Stock	Disposition	2021-02-18	48	$274.63	2,981	No	4	S	Direct
Common Stock	Disposition	2021-02-18	32	$276.23	2,949	No	4	S	Direct
Common Stock	Disposition	2021-02-18	65	$278.27	2,884	No	4	S	Direct
Common Stock	Disposition	2021-02-18	73	$279.20	2,811	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.90 to $264.22,inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.08 to $266.02,inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.44 to $266.96,inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.63 to $268.59,inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $268.69 to $269.68,inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $269.75 to $270.24,inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.82 to $271.61,inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.90 to $272.77,inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.54 to $273.67,inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.91 to $278.62,inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.
The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $279.00 to $279.41,inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in thisfootnote.